Literature DB >> 32962856

NT5DC2 suppression restrains progression towards metastasis of non-small-cell lung cancer through regulation p53 signaling.

Xiang Jin1, Xingang Liu2, Zhen Zhang3, Lijun Xu4.   

Abstract

Non-small cell lung cancer (NSCLC) is a leading cause of tumor mortality worldwide. Nevertheless, the molecular mechanisms revealing NSCLC progression are still unclear. 5'-Nucleotidase domain containing 2 (NT5DC2), as a member of the NT5DC family, contains a haloacid dehalogenase motif localized in the N-terminus of these proteins. NT5DC2 plays an essential role in cancer development. The purpose of the study was to explore NT5DC2's role in tumorigenesis and its potential mechanisms in NSCLC. Our findings showed that NT5DC2 expression was significantly up-regulated in clinical NSCLC tissues compared to the paired non-tumor tissues. Functionally, NT5DC2 knockdown in A549 and H1299 cells markedly reduced cell proliferation, migration and invasion. On the contrary, NT5DC2 over-expression promoted NSCLC cell proliferative, migrative and invasive capacities. Additionally, NT5DC2 down-regulation significantly induced the G2 cell cycle arrest and apoptosis in NSCLC cells. Mechanistically, p53 might be a target of NT5DC2. The expression of p53 was highly induced in NSCLC cells with NT5DC2 knockdown, and opposite result was detected when NT5DC2 was over-expressed. Importantly, we found that NT5DC2 knockdown-restrained cell proliferation and -induced apoptosis was almost abrogated by p53 down-regulation in NSCLC cells, demonstrating that NT5DC2-regulated cell proliferation and apoptotic cell death in NSCLC was p53-dependent. Finally, we confirmed that reducing NT5DC2 could inhibit NSCLC tumorigenesis and hepatic metastasis in vivo. Collectively, these results suggested that NT5DC2 may be a potential driver of NSCLC, providing a new therapeutic target for the clinical treatment of NSCLC.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Apoptosis; Metastasis; NSCLC; NT5DC2; p53

Mesh:

Substances:

Year:  2020        PMID: 32962856     DOI: 10.1016/j.bbrc.2020.06.139

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

1.  A novel immune-related gene signature predicting survival in sarcoma patients.

Authors:  Haoyu Ren; Alexandr V Bazhin; Elise Pretzsch; Sven Jacob; Haochen Yu; Jiang Zhu; Markus Albertsmeier; Lars H Lindner; Thomas Knösel; Jens Werner; Martin K Angele; Florian Bösch
Journal:  Mol Ther Oncolytics       Date:  2021-12-09       Impact factor: 7.200

2.  Decreased RNA‑binding protein IGF2BP2 downregulates NT5DC2, which suppresses cell proliferation, and induces cell cycle arrest and apoptosis in diffuse large B‑cell lymphoma cells by regulating the p53 signaling pathway.

Authors:  Yuying Cui; Yu Wen; Chao Lv; Dongmei Zhao; Yu Yang; Hongbin Qiu; Chennan Wang
Journal:  Mol Med Rep       Date:  2022-07-27       Impact factor: 3.423

3.  Comprehensive Analysis of Prognostic Value and Immune Infiltration of the NT5DC Family in Hepatocellular Carcinoma.

Authors:  Rongqi Li; Rongqiang Liu; Shiyang Zheng; Wenbin Liu; Hui Li; Dewei Li
Journal:  J Oncol       Date:  2022-01-10       Impact factor: 4.375

4.  High Expression of NT5DC2 Is a Negative Prognostic Marker in Pulmonary Adenocarcinoma.

Authors:  Arik Bernard Schulze; Anna Kuntze; Lars Henning Schmidt; Michael Mohr; Alessandro Marra; Ludger Hillejan; Christian Schulz; Dennis Görlich; Wolfgang Hartmann; Annalen Bleckmann; Georg Evers
Journal:  Cancers (Basel)       Date:  2022-03-09       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.